ARWR vs. IDYA, CRNX, XENE, BHC, FOLD, MLTX, ACAD, HCM, MOR, and EVO
Should you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include IDEAYA Biosciences (IDYA), Crinetics Pharmaceuticals (CRNX), Xenon Pharmaceuticals (XENE), Bausch Health Companies (BHC), Amicus Therapeutics (FOLD), MoonLake Immunotherapeutics (MLTX), ACADIA Pharmaceuticals (ACAD), HUTCHMED (HCM), MorphoSys (MOR), and Evotec (EVO). These companies are all part of the "pharmaceutical preparations" industry.
IDEAYA Biosciences (NASDAQ:IDYA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.
IDEAYA Biosciences has higher earnings, but lower revenue than Arrowhead Pharmaceuticals. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
IDEAYA Biosciences currently has a consensus target price of $46.60, indicating a potential upside of 14.64%. Arrowhead Pharmaceuticals has a consensus target price of $50.80, indicating a potential upside of 119.63%. Given IDEAYA Biosciences' higher probable upside, analysts clearly believe Arrowhead Pharmaceuticals is more favorable than IDEAYA Biosciences.
In the previous week, Arrowhead Pharmaceuticals had 3 more articles in the media than IDEAYA Biosciences. MarketBeat recorded 5 mentions for Arrowhead Pharmaceuticals and 2 mentions for IDEAYA Biosciences. IDEAYA Biosciences' average media sentiment score of 0.10 beat Arrowhead Pharmaceuticals' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.
Arrowhead Pharmaceuticals received 410 more outperform votes than IDEAYA Biosciences when rated by MarketBeat users. However, 67.47% of users gave IDEAYA Biosciences an outperform vote while only 65.25% of users gave Arrowhead Pharmaceuticals an outperform vote.
IDEAYA Biosciences has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Arrowhead Pharmaceuticals has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
Arrowhead Pharmaceuticals has a net margin of -163.32% compared to Arrowhead Pharmaceuticals' net margin of -483.05%. Arrowhead Pharmaceuticals' return on equity of -23.00% beat IDEAYA Biosciences' return on equity.
98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 5.1% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 4.5% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
IDEAYA Biosciences beats Arrowhead Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Arrowhead Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arrowhead Pharmaceuticals Competitors List
Related Companies and Tools
